Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital.

BACKGROUND: Immune checkpoint inhibitors (ICI) have been associated with several immune-related adverse events, including sarcoidosis-like reactions (SLR). SLR, which has a low prevalence but an increasing incidence, is similar to sarcoidosis in terms of histology, and clinical and radiological manifestations. The most commonly affected organs are hilar and mediastinal lymph nodes and skin. SLR is an exclusion diagnosis, so a lymph node biopsy can be useful to distinguish between tumor progression and SLR, particularly in tumors in which nodal involvement is very common. PATIENTS AND METHODS: We performed a retrospective analysis of SLR in all cancer patients receiving ICIs in our institution between January 2016 and June 2020. RESULTS: Among the 1063 treated patients, seven experienced SLR, four of whom were symptomatic (cough, skin lesions, arthralgia), with time to onset ranging from 1.5 to 6.7 months after ICI initiation. All seven patients had bilateral hilar lymphadenopathy, and granulomatous reactions in five of the six patients with lymph node biopsies. SLR improved in all patients, including four patients who continued with ICI. Three patients received corticosteroids and/or stopped ICI therapy. Four of these patients had partial responses at the time SLR was identified. CONCLUSION: Management of SLR lacks a consensus recommendation, although corticosteroids and/or stopping the ICI are generally implemented. The potential consequences of stopping anticancer treatment should be taken into consideration, particularly in the absence of clear management recommendations.

[Variations in the prevalence and patient profile of white-coat syndrome, according to its definition using self-measurement of blood pressure at home]. / Variaciones de la prevalencia y el perfil del paciente con fenómeno de bata blanca, según su definición con automedida de presión arterial domiciliaria (AMPA).

OBJECTIVE: To calculate the prevalence of white-coat syndrome (WCS) in patients with hypertension, comparing the two most common definitions and their effect on the profile of the patient with WCS. DESIGN: Cross-sectional, descriptive study.Setting. Urban health centre.Patients. Hypertense patients selected by simple randomised sampling from among those included in the hypertension programme. MEASUREMENTS: Clinical blood pressure (CBP) from the previous year was collected. Home blood pressure (HBP) was measured by the patient with an electronic sphygmomanometer. Age, sex, further tests (analysis and electrocardiogram) and other clinical features were also recorded. WCS was defined as when CBP was above/equal to 140/90 mmHg and HBP was under 135/85 mmHg or when the difference between CBP and HBP was more than/equal to 20 mmHg systolic and/or 10 mmHg diastolic pressure. RESULTS: In 154 hypertense patients (60.4% women) between 38 and 92 years old, mean CBP (141.1/85.3) was higher than mean HBP (136.8/79.8). WCS prevalence varied (p = 0.001), depending on the definition used (20.1% and 36.4%). The systolic and diastolic mean CBP of the last year were higher in those patients with WCS (p < 0.001 for diastolic pressure). The profile of hypertense patients with WCS varied according to the definition used. CONCLUSIONS: WCS is common in hypertense patients treated in Primary Care and may condition an inadequate assessment of the degree of blood pressure monitoring. As the way of defining WCS conditions its prevalence, its profile and clinical decision-taking, it is essential to agree a uniform definition for practical use.